A study of over 410,000 individuals has revealed a continued association between current smoking and a reduced risk of developing Parkinson’s disease, while simultaneously demonstrating that quitting smoking correlates with a lower risk of mortality, according to research published in February 2026.
The findings, initially reported by Medicalxpress.com, revisit what researchers have termed the “smoking paradox” – the counterintuitive observation that smokers exhibit a lower incidence of Parkinson’s disease despite the well-established health risks of smoking. The new study reinforces earlier observations, including a nine-year Korean study highlighted by MedPage Today, which pinpointed current smoking status as the key factor in reducing Parkinson’s risk, rather than past smoking habits.
Researchers at Massachusetts General Hospital have been investigating the neuroprotective mechanisms potentially at play. A 2024 article published in Mov Disord, and summarized by the National Center for Biotechnology Information (NCBI), details growing evidence suggesting a biological basis for the association. The article, authored by Kenneth N. Rose, Michael A. Schwarzschild, and Stephen N. Gomperts, notes that the link between smoking and Parkinson’s disease represents one of the strongest environmental associations identified in neuroepidemiology.
Yet, the benefits of reduced Parkinson’s risk associated with smoking are starkly contrasted by the increased risk of death for smokers, as highlighted in the recent Medscape report. This duality underscores the complex relationship between lifestyle factors and neurological disease, and presents a challenge for public health messaging. The Medscape article specifically notes that quitting smoking is linked to lower all-cause mortality.
The precise mechanisms underlying the neuroprotective effect of smoking remain unclear. The Mov Disord article indicates ongoing research into the biological pathways involved, but a definitive explanation has yet to emerge. The study authors, affiliated with the Department of Neurology at Massachusetts General Hospital, have not yet issued a statement regarding the implications of the latest mortality data.
